Animal models in use by the NCI PREVENT Cancer Preclinical Drug Development Program.

被引：0
|
作者：
Mohammed, Altaf [1 ]
Miller, Mark Steven [1 ]
Glaze, Elizabeth [1 ]
Fernando, Romaine I. [1 ]
Fox, Jennifer [1 ]
Lubet, Ronald A. [1 ]
Sei, Shizuko [1 ]
Shoemaker, Robert H. [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 10期
关键词：
D O I：
10.1158/1538-7445.MOUSEMODELS17-B48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B48
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [31] The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies
    Guo, Haochuan
    Xu, Xinru
    Zhang, Jiaxi
    Du, Yajing
    Yang, Xinbing
    He, Zhiheng
    Zhao, Linjie
    Liang, Tingming
    Guo, Li
    [J]. PHARMACEUTICALS, 2024, 17 (08)
  • [32] Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models
    Settanni, Carlo R.
    Quaranta, Gianluca
    Bibbo, Stefano
    Gasbarrini, Antonio
    Cammarota, Giovanni
    Ianiro, Gianluca
    [J]. MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2020, 66 (01) : 48 - 69
  • [33] Arsenic trioxide in relapsed or refractory Acute Promyelocytic Leukemia - An NCI special exception (compassionate use) program.
    Shalabi, AM
    Fallavollita, A
    Cheson, BD
    Edwards, M
    Plante, M
    Huntley, C
    Phalen, K
    Mungo, AJ
    [J]. BLOOD, 2001, 98 (11) : 596A - 596A
  • [34] Operationalizing the Use of Biofabricated Tissue Models as Preclinical Screening Platforms for Drug Discovery and Development
    Jung, Olive
    Song, Min Jae
    Ferrer, Marc
    [J]. SLAS DISCOVERY, 2021, 26 (09) : 1164 - 1176
  • [35] ANIMAL-MODELS OF OSTEO-ARTHRITIS - POSSIBLE APPLICATIONS IN A DRUG DEVELOPMENT PROGRAM
    STEINETZ, BG
    COLOMBO, C
    BUTLER, MC
    OBYRNE, E
    STEELE, RE
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1981, 30 : S60 - S75
  • [36] Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
    Johnson, JI
    Decker, S
    Zaharevitz, D
    Rubinstein, LV
    Venditti, J
    Schepartz, S
    Kalyandrug, S
    Christian, M
    Arbuck, S
    Hollingshead, M
    Sausville, EA
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (10) : 1424 - 1431
  • [37] The cancer preventive agent identification and early development program at the NCI
    Crowell, J.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 10 - 10
  • [38] Use of Preclinical Models to Assess the Therapeutic Potential of New Drug Candidates for Bladder Cancer
    Amit, Doron
    Gofrit, Ofer N.
    Matouk, Imad
    Birman, Tatiana
    Hochberg, Abraham
    [J]. SEMINARS IN ONCOLOGY, 2012, 39 (05) : 534 - 542
  • [39] Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
    J I Johnson
    S Decker
    D Zaharevitz
    L V Rubinstein
    J M Venditti
    S Schepartz
    S Kalyandrug
    M Christian
    S Arbuck
    M Hollingshead
    E A Sausville
    [J]. British Journal of Cancer, 2001, 84 : 1424 - 1431
  • [40] Development and implementation of a peer evaluation teaching protocol in a large animal science program.
    Huff-Lonergan, E. J.
    Cunnick, J. E.
    Johnson, A. K.
    Sterle, J. A.
    [J]. JOURNAL OF ANIMAL SCIENCE, 2017, 95 : 355 - 356
12345